Gabon Pharmaceuticals and Healthcare Report Q4 2017
The lack of domestic drug manufacturers in Gabon remains an issue. Locally producedmedicines remain underrepresented and drug shortages are commonplace. The country runs a negativetrade balance much like its Sub-Saharan African neighbours. While we expect to see government incentivesthat will encourage the local production of pharmaceuticals to be put in place, medicine shortages willpersist, especially in rural areas.
Headline Expenditure Projections
Pharmaceuticals: XAF51.2bn (USD86mn) in 2016 to XAF53.2bn (USD89mn) in 2017; +3.9% in localcurrency and 3.3% in US dollar terms. Forecast in US dollar terms revised slightly up from last quarter.
Healthcare: XAF329.1bn (USD555mn) in 2016 to XAF349.7bn (USD586mn) in 2017; +6.3% in localcurrency and 5.7% in US dollar terms. Forecast in US dollar terms revised upwards from last quarter.
Moroccan drugmaker Pharma 5 launched a new copy Hepatitis B medication tenofovir, which will be 10times cheaper than the branded version, according to the manufacturer. Previously Pharma 5manufactured and launched three hepatitis C medications, Le SSB 400 (Sofosbuvir), Dakasvir(Daclatasvir), and Rivabir (Ribavirine) in several African countries including Gabon.